# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K220728   
B Applicant Siemens Healthcare Diagnostics Products GmbH   
C Proprietary and Established Names vWF Ag   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>GGP</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 864.7290 - FactorDeficiency Test</td><td rowspan=1 colspan=1>HE - Hematology</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: Clearance of a new device   
B Measurand: VWF:Ag   
C Type of Test:

Immunoturbidimetric assay for the quantitative, WHO-standardized determination of von Willebrand factor (VWF) antigen concentration.

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

In-vitro diagnostic automated assay for the quantitative determination of the von Willebrand antigen (VWF:Ag) in human plasma collected from venous blood samples in $3 . 2 \%$ sodium citrated tubes on the SYSMEX CS-2500 analyzer.

As an aid used in the evaluation of patients aged 4 weeks and older with suspected or confirmed von Willebrand factor disorders and intended for prescription use.

Results of this test should always be interpreted in conjunction with the patient’s medical history, clinical presentation and other laboratory findings.

C Special Conditions for Use Statement(s): Rx - For Prescription Use Only

D Special Instrument Requirements: SYSMEX Automated Blood Coagulation Analyzer CS-2500 (K172286)

IV Device/System Characteristics:

# A Device Description:

Assay and Reagents   
The vWF Ag is an immunoturbidimetric assay for the quantitative determination of von Willebrand factor (VWF) antigen levels.

The vWF Ag kit consists of a ready to use Latex Reagent ( $4 \times 2 ~ \mathrm { m L }$ vials / kit) which is a suspension of small polystyrene particles (latex) coated with rabbit anti-human VWF antibodies. The Reagent Diluent $\mathrm { 4 \times 4 \ : m L }$ vials $/ \operatorname { k i t } ]$ is provided within the kit which is a solution containing glycine. The Reagent Diluent is intended for dilution of the Latex Reagent. The vWF Ag kit is completed by the Buffer $\mathrm { ~ 4 ~ x ~ 5 ~ m L }$ vials / kit) which is a glycine buffer. All components contain sodium azide $( > 1 \ \mathrm { g / L } )$ as a preservative.

# B Principle of Operation:

The small polystyrene particles to which rabbit anti-human vWF antibodies have been attached by covalent bonding are aggregated when mixing with samples containing von Willebrand antigen. This aggregation is then detected turbidimetrically by the Sysmex CS-2500 analyzer, via the increase in turbidity, which is proportional to the antigen level present in the test sample.

# V Substantial Equivalence Information:

A Predicate Device Name(s): Sta - Liatest vWF Test Kit

# B Predicate 510(k) Number(s): K962675

# C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">K220728</td><td colspan="1" rowspan="1">K962675</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">vWF Ag</td><td colspan="1" rowspan="1">STA-Liatest VWF:Ag</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Similarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use/IndicationsFor Use</td><td colspan="1" rowspan="1">In-vitro diagnosticautomated assay for thequantitativedetermination of thevon Willebrand antigen(VWF:Ag) in humanplasma collected fromvenous blood samplesin 3.2% sodium citratedtubes on the SYSMEXCS-2500 analyzer.As an aid used in theevaluation of patientswith suspected orconfirmed vonWillebrand factordisorders and intendedfor prescription use.Results of this testshould always beinterpreted inconjunction with thepatient's medicalhistory, clinicalpresentation and otherlaboratory findings.</td><td colspan="1" rowspan="1">The STA - LiatestVWF:Ag kit is intendedfor use with STA-R®and STA Compact, forthe quantitativedetermination of vonWillebrand factorantigen (VWF:Ag) inplasma by the immuno-turbidimetric method.</td></tr><tr><td colspan="1" rowspan="1">Measurand</td><td colspan="1" rowspan="1">VWF:Ag</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Unit</td><td colspan="1" rowspan="1">% of norm(100% of norm equals1.00 IU)</td><td colspan="1" rowspan="1">%(100% equals 1.00 IU)</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Citrated human plasmafrom venous bloodCitrated platelet poorhuman plasma</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Shelf Life</td><td colspan="1" rowspan="1">18 months at 2  8°C</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Differences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Classification Product Code</td><td colspan="1" rowspan="1">GGP</td><td colspan="1" rowspan="1">GJT</td></tr><tr><td colspan="1" rowspan="1">Measuring Interval</td><td colspan="1" rowspan="1">4 - 300% of norm</td><td colspan="1" rowspan="1">3 - 420%</td></tr><tr><td colspan="1" rowspan="1">Control Level</td><td colspan="1" rowspan="1">3 Control levels(sold separately fromthe assay):Control Plasma N(K042333, normalrange)Control Plasma P andControl Plasma P 1:6diluted (K042209,pathological range)</td><td colspan="1" rowspan="1">2 Control levels(sold separately fromthe assay):STA-Liatest Control N(normal range)STA-Liatest Control P(pathological range)</td></tr><tr><td colspan="1" rowspan="1">Test Principleanalyzer measuringprinciple(wavelength)</td><td colspan="1" rowspan="1">Immuno-turbidimetry(660 nm)</td><td colspan="1" rowspan="1">Immuno-turbidimetry(540 nm)</td></tr><tr><td colspan="1" rowspan="1">Test Principle (biochemicalprinciple of reagent)</td><td colspan="1" rowspan="1">Small polystyreneparticles to whichspecific antibodies havebeen attached bycovalent bonding areaggregated whenmixing with samplescontaining vonWillebrand antigen.This aggregation is thendetectedturbidimetrically via theincrease in turbidity,which is proportional tothe antigen level presentin the test sample.</td><td colspan="1" rowspan="1">This assay is based onthe change in turbidityof a microparticlesuspension that ismeasured byphotometry. Asuspension of latexmicroparticles, coatedby covalent bondingwith antibodies specificfor VWF, is mixed withthe test plasma whoseVWF antigen level is tobe assayed. An antigen-antibody reaction takesplace, leading to anagglutination of thelatex microparticleswhich induces anincrease in turbidity ofthe reaction medium.This increase inturbidity is reflected by</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">absorbance, the latterbeing measuredphotometrically. Theincrease in absorbanceis a function of theVWF level present inthe test sample.</td></tr><tr><td colspan="1" rowspan="1">Reagents</td><td colspan="1" rowspan="1">vWF Ag Buffer:- Glycine buffer- Sodium azide (&lt; 1g/L)vWF Ag LatexReagent:- Suspension of smallpolystyrene particlescoated with rabbit anti-human VWFantibodies.- Sodium azide (&lt; 1g/L)vWF Ag Diluent forLatex Reagent:- Solution containingglycine intended fordilution of the LatexReagent- Sodium azide (&lt; 1g/L)</td><td colspan="1" rowspan="1">Reagent 1:- Glycine buffer- Sodium azide (&lt; 1g/L)Reagent 2:- Suspension ofmicrolatex particlescoated with rabbitantihuman VWFantibodies- Sodium azide (&lt; 1g/L)Reagent 3:- Solution containingglycine for dilution ofLatex reagent (Reagent2- Sodium azide (&lt; 1g/L)</td></tr><tr><td colspan="1" rowspan="1">Buffer</td><td colspan="1" rowspan="1">Dade Owren's VeronalBuffer</td><td colspan="1" rowspan="1">STA - Owren-Koller</td></tr><tr><td colspan="1" rowspan="1">Stability Once Opened</td><td colspan="1" rowspan="1">4 weeks at 2  8°</td><td colspan="1" rowspan="1">Not specified inpackage insert</td></tr><tr><td colspan="1" rowspan="1">On Board Stability</td><td colspan="1" rowspan="1">In original vials thevWF Ag Reagent andvWF Ag Buffer may beleft on board theinstrument for 100hours. The reagent vialscan stay continuouslyon board or be removed</td><td colspan="1" rowspan="1">With STA - miniReducer and perforatedcap in place the stabilityof Reagent 2 afterdilution is 15 days onSTA-R and STACompact.</td></tr><tr><td></td><td>and stored closed at 2 to 8°C before the next placement on board for a total of 100 hours.</td><td></td></tr><tr><td>Sample Stability</td><td>Maximal storage at 15 to 25°C in primary cups (plasma stored over cells) = 4 hours Maximal storage at 15 to 25°C in secondary cup (plasma siphoned from cells) = 4 hours Maximal storage at ≤ - 20°C in secondary cups (plasma siphoned from cells) = 3 months Maximal storage at ≤ - 74°C in secondary cups (plasma siphoned from cells) = 6 months Furthermore, the 510(k) data confirms that once frozen samples can be measured within 4</td><td>•8 hours at 20 ± 5° •24 hours at 2  8°C 1 month at -20°C.</td></tr></table>

# VI Standards/Guidance Documents Referenced:

CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline – Second Edition

CLSI EP25-A: Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline

CLSI EP06-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline

CLSI EP07: Interference Testing in Clinical Chemistry, 3rd Edition

CLSI EP37: Supplemental Tables for Interference Testing in Clinical Chemistry, 1st Edition

CLSI EP28-A3c: Defining, Establishing, and Verifying Reference Intervals in Clinical Laboratory; Approved Guideline – Third Edition

CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline – Third Edition

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

Repeatability (Single site): A single-site (internal) precision study was performed for the performance evaluation of vWF Ag. The study was performed on 20 days with two runs per day and two replicates $( 2 0 \times 2 \times 2 )$ of each sample per run on one SYSMEX CS-2500 analyzer. One reagent lot was investigated in combination with three calibrator lots, in addition, one calibrator lot was investigated in combination with three reagent lots for a total of 240 determinations (i.e., 80 determinations per reagent or calibrator lot). Three plasma pools (PP1–3) as well as three control materials (CPN, CPP, CPP 1:6 dilution) were investigated as test samples. The samples were chosen to cover the respective measuring interval of vWF $\mathrm { A g }$ (4 to $300 \%$ of norm) and the medical decision levels ( $30 \%$ of norm, $50 \%$ of norm). All measurands met the predefined acceptance criteria. The results for within-run, between-lot and total imprecision are presented in the summary tables below.

Table 1. Evaluation of $3 { \bf x } 2 0 { \bf x } 2 { \bf x } 2$ Precision Study at Single Site – investigation of reagent variability.   

<table><tr><td rowspan=3 colspan=1>Sample</td><td rowspan=3 colspan=1>N</td><td rowspan=3 colspan=1>Mean(% ofnorm)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Reagent Lot</td><td rowspan=1 colspan=2>Within-Laboratory</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>CPP 1:6</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>6.31</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>3.13</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>2.67</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.87</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>4.20</td></tr><tr><td rowspan=1 colspan=1>PP1</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>25.26</td><td rowspan=1 colspan=1>0.77</td><td rowspan=1 colspan=1>3.07</td><td rowspan=1 colspan=1>0.46</td><td rowspan=1 colspan=1>1.82</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>0.87</td><td rowspan=1 colspan=1>0.71</td><td rowspan=1 colspan=1>2.81</td><td rowspan=1 colspan=1>1.17</td><td rowspan=1 colspan=1>4.62</td></tr><tr><td rowspan=1 colspan=1>CPP</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>39.74</td><td rowspan=1 colspan=1>2.65</td><td rowspan=1 colspan=1>6.68</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>1.88</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>2.48</td><td rowspan=1 colspan=1>2.93</td><td rowspan=1 colspan=1>7.37</td></tr><tr><td rowspan=1 colspan=1>PP2</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>52.26</td><td rowspan=1 colspan=1>0.69</td><td rowspan=1 colspan=1>1.32</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>0.46</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>1.76</td><td rowspan=1 colspan=1>1.32</td><td rowspan=1 colspan=1>2.53</td></tr><tr><td rowspan=1 colspan=1>CPN</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>135.46</td><td rowspan=1 colspan=1>2.53</td><td rowspan=1 colspan=1>1.86</td><td rowspan=1 colspan=1>1.44</td><td rowspan=1 colspan=1>1.06</td><td rowspan=1 colspan=1>1.74</td><td rowspan=1 colspan=1>1.29</td><td rowspan=1 colspan=1>2.67</td><td rowspan=1 colspan=1>1.97</td><td rowspan=1 colspan=1>4.32</td><td rowspan=1 colspan=1>3.19</td></tr><tr><td rowspan=1 colspan=1>PP3</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>285.79</td><td rowspan=1 colspan=1>4.98</td><td rowspan=1 colspan=1>1.74</td><td rowspan=1 colspan=1>4.98</td><td rowspan=1 colspan=1>1.74</td><td rowspan=1 colspan=1>1.85</td><td rowspan=1 colspan=1>0.65</td><td rowspan=1 colspan=1>9.19</td><td rowspan=1 colspan=1>3.22</td><td rowspan=1 colspan=1>11.73</td><td rowspan=1 colspan=1>4.10</td></tr></table>

Table 2. Evaluation of $3 { \bf x } 2 0 { \bf x } 2 { \bf x } 2$ Precision Study at Single Site – investigation of calibrator variability.   

<table><tr><td rowspan=3 colspan=1>Sample</td><td rowspan=3 colspan=1>N</td><td rowspan=3 colspan=1>Mean(% ofnorm)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Calibrator Lot</td><td rowspan=1 colspan=2>Within-Laboratory</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>CPP1:6</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>6.44</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>2.32</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>2.94</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>4.73</td><td rowspan=1 colspan=1>0.39</td><td rowspan=1 colspan=1>6.03</td></tr><tr><td rowspan=1 colspan=1>PP1</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>25.48</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>0.93</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.80</td><td rowspan=1 colspan=1>3.14</td><td rowspan=1 colspan=1>0.90</td><td rowspan=1 colspan=1>3.53</td></tr><tr><td rowspan=1 colspan=1>CPP</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>38.02</td><td rowspan=1 colspan=1>2.30</td><td rowspan=1 colspan=1>6.06</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.59</td><td rowspan=1 colspan=1>1.55</td><td rowspan=1 colspan=1>1.09</td><td rowspan=1 colspan=1>2.87</td><td rowspan=1 colspan=1>2.62</td><td rowspan=1 colspan=1>6.88</td></tr><tr><td rowspan=1 colspan=1>PP2</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>51.38</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>0.44</td><td rowspan=1 colspan=1>0.85</td><td rowspan=1 colspan=1>0.61</td><td rowspan=1 colspan=1>1.18</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>1.79</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>2.55</td></tr><tr><td rowspan=1 colspan=1>CPN</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>133.00</td><td rowspan=1 colspan=1>1.89</td><td rowspan=1 colspan=1>1.42</td><td rowspan=1 colspan=1>1.63</td><td rowspan=1 colspan=1>1.23</td><td rowspan=1 colspan=1>2.01</td><td rowspan=1 colspan=1>1.51</td><td rowspan=1 colspan=1>1.45</td><td rowspan=1 colspan=1>1.09</td><td rowspan=1 colspan=1>3.52</td><td rowspan=1 colspan=1>2.64</td></tr><tr><td rowspan=1 colspan=1>PP3</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>276.99</td><td rowspan=1 colspan=1>4.78</td><td rowspan=1 colspan=1>1.73</td><td rowspan=1 colspan=1>4.43</td><td rowspan=1 colspan=1>1.60</td><td rowspan=1 colspan=1>2.69</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>5.72</td><td rowspan=1 colspan=1>2.07</td><td rowspan=1 colspan=1>9.08</td><td rowspan=1 colspan=1>3.28</td></tr></table>

Precision study (Single site, for Instrument/Operator Variability): This study was conducted to evaluate instrument/operator variability at one internal site. This study was conducted on five days, with two runs per day and four replicates of each sample per run $( 5 \times 2 \times$ 4) on three SYSMEX CS-2500 analyzers for a total of 120 determinations (i.e., 40 determinations per instrument/operator combination). The study investigated one reagent/calibrator lot combination on all three SYSMEX CS-2500 analyzers.

Three plasma pools (PP1–3) as well as three control materials (CPN, CPP, CPP 1:6 dilution) were investigated as test samples. The samples were chosen to cover the respective measuring interval of vWF $\mathbf { A } \mathbf { g }$ (4 to $3 0 0 \%$ of norm) and the medical decision levels ( $30 \%$ of norm, $50 \%$ of norm). All measurands met the predefined acceptance criteria The results for within-run, between-instrument/operator and total imprecision are provided in the summary table below.

Table 3. Evaluation of $3 \mathbf { x } 5 \mathbf { x } 2 \mathbf { x } 4$ precision study for vWF Ag on the SYSMEX CS-2500 analyzer at single site; instrument/operator combined.   

<table><tr><td rowspan=3 colspan=1>Sample</td><td rowspan=3 colspan=1>N</td><td rowspan=3 colspan=1>Mean(% ofnorm)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Within- Site</td><td rowspan=1 colspan=2>Between-Site</td><td rowspan=1 colspan=2>Within-Laboratory</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>CPP1:6</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>7.49</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>2.82</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>1.42</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>3.16</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>1.29</td><td rowspan=1 colspan=1>0.26</td><td rowspan=1 colspan=1>3.41</td></tr><tr><td rowspan=1 colspan=1>PP1</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>24.34</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>1.27</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>0.65</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.35</td><td rowspan=1 colspan=1>1.42</td><td rowspan=1 colspan=1>0.61</td><td rowspan=1 colspan=1>2.52</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>2.90</td></tr><tr><td rowspan=1 colspan=1>CPP</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>42.83</td><td rowspan=1 colspan=1>1.84</td><td rowspan=1 colspan=1>4.28</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>1.65</td><td rowspan=1 colspan=1>1.97</td><td rowspan=1 colspan=1>4.59</td><td rowspan=1 colspan=1>1.63</td><td rowspan=1 colspan=1>3.79</td><td rowspan=1 colspan=1>2.55</td><td rowspan=1 colspan=1>5.96</td></tr><tr><td rowspan=1 colspan=1>PP2</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>49.04</td><td rowspan=1 colspan=1>0.73</td><td rowspan=1 colspan=1>1.48</td><td rowspan=1 colspan=1>0.43</td><td rowspan=1 colspan=1>0.87</td><td rowspan=1 colspan=1>0.48</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>1.97</td><td rowspan=1 colspan=1>1.19</td><td rowspan=1 colspan=1>2.43</td><td rowspan=1 colspan=1>1.53</td><td rowspan=1 colspan=1>3.13</td></tr><tr><td rowspan=1 colspan=1>CPN</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>129.91</td><td rowspan=1 colspan=1>3.03</td><td rowspan=1 colspan=1>2.33</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>1.92</td><td rowspan=1 colspan=1>1.48</td><td rowspan=1 colspan=1>3.59</td><td rowspan=1 colspan=1>2.77</td><td rowspan=1 colspan=1>1.06</td><td rowspan=1 colspan=1>0.81</td><td rowspan=1 colspan=1>3.75</td><td rowspan=1 colspan=1>2.88</td></tr><tr><td rowspan=1 colspan=1>PP3</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>259.77</td><td rowspan=1 colspan=1>2.95</td><td rowspan=1 colspan=1>1.14</td><td rowspan=1 colspan=1>2.60</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>2.73</td><td rowspan=1 colspan=1>1.05</td><td rowspan=1 colspan=1>4.78</td><td rowspan=1 colspan=1>1.84</td><td rowspan=1 colspan=1>2.23</td><td rowspan=1 colspan=1>0.86</td><td rowspan=1 colspan=1>5.28</td><td rowspan=1 colspan=1>2.03</td></tr></table>

Reproducibility (multi-site): The external reproducibility study was carried out at three external sites, on five days, with two runs per day and three replicates of each sample per run $( 3 \mathrm { ~ x ~ } 5 \mathrm { ~ x ~ } 2 \mathrm { ~ x ~ } 3 )$ for a total of 90 determinations (i.e., 30 determinations per site). All external sites performed the reproducibility study with the same reagent/calibrator lot combination. Three plasma pools (PP1–3) as well as three control materials (CPN, CPP, CPP 1:6 dilution) were investigated as test samples. The samples were chosen to cover the respective measuring interval of vWF $\mathrm { A g }$ (4 to $3 0 0 \%$ of norm) and the medical decision levels ( $30 \%$ of norm, $50 \%$ of norm). All measurands met the predefined acceptance criteria. The results for within-run, between-laboratory and total imprecision are provided in the summary table below.

Table 4. Evaluation of 3x5x2x3 Reproducibility study for vWF Ag on the SYSMEX CS-2500 analyzer; all three external (US) sites combined.   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(% ofnorm)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Instrument/Operator</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>CPP1:6</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>6.51</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>1.51</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.87</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>1.77</td></tr><tr><td rowspan=1 colspan=1>PP1</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>22.65</td><td rowspan=1 colspan=1>0.35</td><td rowspan=1 colspan=1>1.55</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>0.59</td><td rowspan=1 colspan=1>2.62</td><td rowspan=1 colspan=1>0.72</td><td rowspan=1 colspan=1>3.19</td></tr><tr><td rowspan=1 colspan=1>CPP</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>37.22</td><td rowspan=1 colspan=1>1.18</td><td rowspan=1 colspan=1>3.16</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.45</td><td rowspan=1 colspan=1>1.20</td><td rowspan=1 colspan=1>1.52</td><td rowspan=1 colspan=1>4.08</td><td rowspan=1 colspan=1>1.97</td><td rowspan=1 colspan=1>5.30</td></tr><tr><td rowspan=1 colspan=1>PP2</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>46.24</td><td rowspan=1 colspan=1>0.78</td><td rowspan=1 colspan=1>1.70</td><td rowspan=1 colspan=1>0.39</td><td rowspan=1 colspan=1>0.83</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>1.52</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>2.12</td><td rowspan=1 colspan=1>1.49</td><td rowspan=1 colspan=1>3.22</td></tr><tr><td rowspan=1 colspan=1>CPN</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>112.78</td><td rowspan=1 colspan=1>1.65</td><td rowspan=1 colspan=1>1.47</td><td rowspan=1 colspan=1>0.78</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>1.75</td><td rowspan=1 colspan=1>1.55</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>2.53</td><td rowspan=1 colspan=1>2.24</td></tr><tr><td rowspan=1 colspan=1>PP3</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>265.54</td><td rowspan=1 colspan=1>6.91</td><td rowspan=1 colspan=1>2.60</td><td rowspan=1 colspan=1>2.50</td><td rowspan=1 colspan=1>0.94</td><td rowspan=1 colspan=1>4.14</td><td rowspan=1 colspan=1>1.56</td><td rowspan=1 colspan=1>7.50</td><td rowspan=1 colspan=1>2.82</td><td rowspan=1 colspan=1>11.29</td><td rowspan=1 colspan=1>4.25</td></tr></table>

# 2. Linearity:

The linearity study was performed following the CLSI $\mathrm { E P 0 6 2 ^ { n d } }$ Ed guideline, on one day, using three SYMEX CS-2500 analyzers with three lots of vWF Ag reagent (one lot per analyzer), and four replicates of each sample (dilution). The dilution series was prepared by mixing a high concentration sample pool (high pool) with a low concentration sample pool (low pool). The high pool was prepared by spiking a normal plasma pool with a VWF concentrate. The VWF deficient plasma was internally produced by immunoaffinity chromatography.

Samples with 12 different dilutions were evaluated in the linearity study. Determination of linearity was performed using weighted linear regression using no intercept in the model. The deviation between the mean measured value and the predicted value of the linear regression was calculated for each sample concentration. The calculated deviations were then compared to the acceptance criteria and the linear range was defined accordingly. The results support the linearity range of 4 to $300 \%$ of norm on the SYSMEX CS-2500 analyzer.

# 3. Analytical Specificity/Interference:

Interference studies were conducted based on the CLSI EP07 3rd edition, and CLSI EP37 1st edition guidelines.

# Endogenous Interference Study:

Dose-response experiments were carried out to determine the degree of interference as a function of the interferent concentration for endogenous interferents hemoglobin, unconjugated bilirubin, conjugated bilirubin, lipids, and rheumatoid factors. The interference study was carried out with one SYSMEX CS-2500 analyzer and one vWF Ag lot. Each VWF antigen level was investigated with five different test samples. Each sample was tested in triplicate on one day and with one lot of Standard Human Plasma (SHP) as calibrator. For testing the interference by human anti-mouse antibodies (HAMAs), 12 test samples (HAMApositive) and 12 control samples (HAMA-positive) were used as per CLSI 1/LA30-A. Similarly, for the potential interference by lupus anticoagulant, 12 test samples (Lupuspositive) and 12 control samples (Lupus-negative) were used. None of the listed endogenous substances in the following table were found to cause interference up to the indicated concentrations:

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>No interference up to:</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>712 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin ( unconjugated)</td><td rowspan=1 colspan=1>30 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (conjugated)</td><td rowspan=1 colspan=1>100 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Lipids*</td><td rowspan=1 colspan=1>549 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factors</td><td rowspan=1 colspan=1>23 IU/mL</td></tr><tr><td rowspan=1 colspan=1>HAMA</td><td rowspan=1 colspan=1>499 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Lupus Anticoagulant</td><td rowspan=1 colspan=1>dRVVT ratio = 2.49</td></tr></table>

Exogenous Interference Study: Interference study on potentially exogenous interfering substances (drug panel) were conducted to evaluate the potential interference of over-the-counter drugs and prescription drugs for the vWF Ag assay on the SYSMEX CS-2500 analyzer. The interference study (drug panel) was carried out with one SYSMEX CS-2500 analyzer and one vWF Ag lot. The maximum concentration of each interferent was determined per CLSI EP37 guideline. None of the substances in the following table (exogenous substances/drug panel) were found to lead to clinically significant interference.

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>No interference up to:</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen (Paracetamol)</td><td rowspan=1 colspan=1>156 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Acetyl salicylic acid</td><td rowspan=1 colspan=1>30 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Amitriptyline hydrochloride</td><td rowspan=1 colspan=1>543 ng/ml</td></tr><tr><td rowspan=1 colspan=1>Atorvastatin calcium salt trihydrate</td><td rowspan=1 colspan=1>812 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Budesonide</td><td rowspan=1 colspan=1>6.3 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Carbimazol</td><td rowspan=1 colspan=1>3.6 μg/ml</td></tr><tr><td rowspan=1 colspan=1>Ciprofloxacin</td><td rowspan=1 colspan=1>12 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Cisplatin</td><td rowspan=1 colspan=1>33 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Citalopram hydrobromide</td><td rowspan=1 colspan=1>6.79 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Clopidogrel hydrogensulfate</td><td rowspan=1 colspan=1>24 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Diclofenac sodium salt</td><td rowspan=1 colspan=1>26 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Emicizumab</td><td rowspan=1 colspan=1>300 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Estradiol</td><td rowspan=1 colspan=1>7.5 pg/mL</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen sodium salt</td><td rowspan=1 colspan=1>240 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Lenalidomide</td><td rowspan=1 colspan=1>2.13 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Lisinopril dihydrate</td><td rowspan=1 colspan=1>268 ng/mL</td></tr><tr><td rowspan=1 colspan=1>L-Thyroxin</td><td rowspan=1 colspan=1>180 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Metformin Hydrochloride</td><td rowspan=1 colspan=1>15.4 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Pantoprazole sodium sesquihydrate</td><td rowspan=1 colspan=1>34 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Progesterone</td><td rowspan=1 colspan=1>540 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Ramipril</td><td rowspan=1 colspan=1>156 ng/mL</td></tr><tr><td rowspan=1 colspan=1>RFVIIa: NovoSeven®((Eptacog alfa activated)</td><td rowspan=1 colspan=1>4.5 μg/mL</td></tr><tr><td rowspan=1 colspan=1>RFVIII: ELOCTA® (Efmoroctocog alfa)</td><td rowspan=1 colspan=1>1.875 IU/mL</td></tr><tr><td rowspan=1 colspan=1>RFVII Eperoc® (Turocg lfa egol)</td><td rowspan=1 colspan=1>1.875 IU/mL</td></tr><tr><td rowspan=1 colspan=1>Tetracycline</td><td rowspan=1 colspan=1>24 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Theophylline</td><td rowspan=1 colspan=1>60 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Thiouracil (2-Thiouracil)</td><td rowspan=1 colspan=1>15.9 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Ticagrelor</td><td rowspan=1 colspan=1>108 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Tranexamic Acid</td><td rowspan=1 colspan=1>162.9 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Valproic Acid</td><td rowspan=1 colspan=1>318 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Valsartan</td><td rowspan=1 colspan=1>11.7 μg/mL</td></tr></table>

4. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

# a. Sample Stability Study

Sample stability study was performed to investigate the sample stability characteristics of the proposed device under defined storage conditions with 23 to 25 samples covering the measuring interval of vWF $\mathbf { A } \mathbf { g }$ (4 to $300 \%$ of norm) at one external study site and one internal study site. 3 out 25 samples belong to $\leq 2 0 \%$ of vWF Ag norm, among which 2 samples were contrived. The remaining 20 samples belong to $5 2 0 \%$ of vWF Ag norm. All sample measurements at storage condition of the sample stability study, except for the measurement after storage at $\le 7 0 ^ { \circ } \mathrm { C }$ , were performed with one reagent lot vWF Ag, one lot calibrator (SHP) as four single determinations on one SYSMEX CS-2500 analyzer at the respective study site. Evaluation of sample stability at $\le - 7 0 ^ { \circ } \mathrm { C }$ were performed with another reagent lot vWF $\mathbf { A } \mathbf { g }$ , and another calibrator lot (SHP) on one SYSMEX CS-2500 analyzer. One calibration curve was established (for each reagent / calibrator lot) and used for the entire sample stability at each study site. The data support a sample stability claim of 4 hours at 15 to $2 5 ^ { \circ } \mathrm { C }$ (primary and secondary cups), 4 hours at 15 to $2 5 ^ { \circ } \mathrm { C }$ (once frozen), 3 months at $\leq - 2 0 ^ { \circ } \mathrm { C }$ , 6 months stability at $\le - 7 0 ^ { \circ } \mathrm { C }$ .

# b. Traceability Study

The objective of this study is to investigate the traceability of the assigned value of SHP to the WHO 6th International Standard (IS) Factor VIII / Von Willebrand Factor (NIBSC code 07/316). The study was carried out with three different reagent lots of the vWF Ag assay, on one SYSMEX CS-2500 analyzer and three SHP lots. Four vials of the WHO 6th International Standard for Factor VIII / Von Willebrand Factor were investigated in single determination on one day and with one trained operator. With each vWF Ag reagent lot three calibration curves were established with the three SHP lots. The accuracy of the calibration curves was assessed by running the appropriate control materials, Control Plasma N (normal) and Control Plasma P (pathologic), before and after the measurements. The predetermined acceptance criterion was fulfilled, confirming that the candidate vWF assay is traceable to WHO 6th International Standard Factor VIII / Von Willebrand Factor (07/316).

# c. Shelf Life Stability of Reagent

The shelf life stability study for vWF Ag was performed in accordance with the CLSI EP25-A, using an isochronous design, where the product was placed under the test storage conditions (2 to $8 ^ { \circ } \mathrm { C }$ ) at the start of the study and then withdrawn for testing at different time points (0, 3, 6, 9, 12, 15, and 18 months) using three lots of vWF Ag vials. Four plasma pools as well as three control materials were investigated as test samples. The samples were chosen to cover the respective measuring interval of vWF $\mathrm { A g }$ (4 to $300 \%$ of norm). The results support a reagent shelf-life stability claim of 18 months when stored at 2 to $8 \mathrm { { } ^ { \circ } C }$ .

# d. Shelf Life Stability of Calibrator

The shelf life stability study for SHP for use as calibrator for vWF Ag was performed according to the CLSI EP25-A. The study was conducted by testing three SHP lots at the following time-points (0, 3, 6, 9, 12, 15, 18, 21, 24 and 25 months). The SHP is placed under the storage conditions (2 to $8 ^ { \circ } \mathrm { C }$ ) at the start of the study and then withdrawn for testing at different time points throughout the study duration. Four to 8 replicates per sample were measured at each time point. The results support a shelflife stability claim of 24 months for SHP, when stored at 2 to $8 \mathrm { { } ^ { \circ } C }$ .

The detection limits of the vWF Ag assay – limit of blank (LoB), limit of detection (LoD), limit of quantitation (LoQ) were determined following the CLSI EP17-A2 guideline.

The LoB study was performed with five independent analyte-free plasma samples internally prepared by immunoaffinity chromatography. The study was carried out with one SYSMEX CS-2500 analyzer, three different reagent lots, one calibrator lot, five analyte-free samples, one single determination of four individual aliquots of each sample on three days, resulting in in 60 measurements per reagent lot, and 180 measurements overall. The results determine the LoB for the vWF Ag as $1 . 0 7 \%$ of norm.

The LoD study was performed with five independent low-analyte samples. The samples were prepared by dilution of a normal plasma sample, to levels within the calibrated range but below $4 \%$ of norm with VWF deficient plasmas. The study was carried out with one SYSMEX CS-2500 analyzer, three different reagent lots, one calibrator lot, five analyte-free samples, one single determination of four individual aliquots of each sample on three days, resulting in in 60 measurements per reagent lot, and 180 measurements overall. The results determine the LoD for the vWF Ag as $1 . 8 1 \%$ of norm.

This LoQ study was with five independent low-analyte samples, by dilution of five 5 different normal plasma samples, with five 5 different VWF:Ag deficient plasma pools resulting in low-analyte samples with 3 to $4 \%$ of norm VWF antigen (assigned value of the LoQ samples). The study was carried out with one SYSMEX CS-2500 analyzer, three different reagent lots, one calibrator lot, five low analyte samples, single determination of four individual aliquots of each sample on three days, resulting in 60 measurements per reagent lot, and 180 measurements overall. The results determine the LoQ for the vWF Ag as $3 . 1 2 \%$ of norm.

6. Assay Cut-Off: Not applicable.

# B Comparison Studies:

# 1. Method Comparison with Predicate Device:

Method comparison studies was performed at three clinical study sites to compare the performance of the vWF Ag assay on the SYSMEX CS-2500 analyzer with the STA - Liatest VWF:Ag assay (K962675) on the STA R Max analyzer (K151867). A total of 370 samples were evaluated from three sites. To support the intended use population, patient samples with various demographics (i.e. age, gender, race/ethnicity), were included in the study. The patient cohort included patients previously diagnosed with von Willebrand disease (VWD) (VWD type 1, VWD type 2 (type 2A, 2B, 2M and 2N), VWD type 3, and patients with acquired VWD), patients with hemophilia A, patient with platelet dysfunction and patients without final VWD related diagnosis at the time of enrollment. All samples were collected in $3 . 2 \%$ sodium citrate anticoagulant and tested in singlet with both methods (subject and comparator). Patient sample demographics included 235 females and 135 males, $\geq 4$ weeks of age. Out of the 370 samples, 339 patients demonstrated VWF:Ag values inside the

measuring interval of the proposed and predicate device and are thus included in the statistical evaluation. The predefined acceptance criteria for Passing-Bablok regression analysis, predicted bias at medical decision points, and Pearson correlation coefficient were achieved.

<table><tr><td rowspan=1 colspan=1>Study Site</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>SampleRange</td><td rowspan=1 colspan=1>Slope(95%CI)</td><td rowspan=1 colspan=1>Intercept (% of norm)(95% CI)</td><td rowspan=1 colspan=1>Pearson correlationcoefficient (r)</td></tr><tr><td rowspan=1 colspan=1>All sites combined</td><td rowspan=1 colspan=1>339</td><td rowspan=1 colspan=1>5.4289.9% of norm</td><td rowspan=1 colspan=1>1.036(1.018, 1.055)</td><td rowspan=1 colspan=1>-4.602(-6.016, -3.509)</td><td rowspan=1 colspan=1>0.982</td></tr></table>

2. Matrix Comparison: Not applicable

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable

2. Clinical Specificity: Not applicable

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable

D Clinical Cut-Off: Not applicable

# E Expected Values/Reference Range:

Reference interval studies for the two subgroups investigated (blood group O and non-O) were conducted at three clinical sites. Citrated plasma samples were obtained from 306 apparently healthy individuals (147 blood group O and 159 blood group non-O) $\geq 1 8$ years of age. At each site the plasma samples were measured with one vWF Ag lot, one SHP lot, on one SYSMEX CS-2500 analyzer, in single determination. Results from all sites were pooled and all reference intervals were established by calculating two-sided $9 5 \%$ central interval (2.5th /97.5th percentiles) as the 97.5th percentile was found within the measuring interval. The results for the generic VWF activity reference interval (pooled data of the multicenter study), ABO blood group-specific reference intervals are summarized in the table below.

Reference Intervals Summary   

<table><tr><td rowspan=1 colspan=1>ABO Blood Group</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>2.5th Percentile(95% confidence interval)</td><td rowspan=1 colspan=1>97.5th Percentile(95% confidence interval)</td></tr><tr><td rowspan=1 colspan=1>ABO blood groupscombined</td><td rowspan=1 colspan=1>306</td><td rowspan=1 colspan=1>50.6%(45.2%, 58.9%)</td><td rowspan=1 colspan=1>271.2%(222.8%, 298.3%)</td></tr><tr><td rowspan=1 colspan=1>Blood group O</td><td rowspan=1 colspan=1>147</td><td rowspan=1 colspan=1>46.6%(32.6%, 54.1%)</td><td rowspan=1 colspan=1>202.1%(153.8%, 295.6%)</td></tr><tr><td rowspan=1 colspan=1>Blood group non-O(groups A, B, AB)</td><td rowspan=1 colspan=1>159</td><td rowspan=1 colspan=1>54.3%(50.1%, 71.8%)</td><td rowspan=1 colspan=1>293.6%(245.7%, *)</td></tr></table>

\*The upper $9 5 \%$ confidence limit for the $9 7 . 5 \mathrm { t h }$ percentile cannot be stated for this subgroup, because corresponding to the sample size of $\mathrm { { n } = 1 5 9 }$ , the highest observation represents the upper limit of the $9 5 \%$ confidence range for the $9 7 . 5 \mathrm { t h }$ percentile. The highest observation in this subgroup was above the measuring interval vWF Ag $( > 3 0 0 \%$ of norm).

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.